<DOC>
	<DOCNO>NCT01912274</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness pracinostat combine azacitadine patient 65 year age old Acute Myelogenous Leukemia ( AML )</brief_summary>
	<brief_title>Safety Efficacy Study Pracinostat With Azacitadine Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Male female subject age ≥65 year . Voluntary write informed consent performance study relate procedure part normal medical care . Newly diagnose de novo , secondary , treatmentrelated AML intermediate unfavorablerisk cytogenetics base Southwest Oncology Group ( SWOG ) classification ( Slovak et al , 2000 ) . One prior cycle therapy approve hypomethylating agent ( HMA ) azacitidine decitabine allow either antecedent hematologic disorder ( AHD ) AML . Patients also eligible receive lenolidamide , immunosuppressive therapy low dose chemotherapy AHD . Prior hydroxyurea allow . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . ≥20 % blast bone marrow . Peripheral WBC &lt; 30,000/uL . Adequate organ function evidence : Total bilirubin 2x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) 2.5x ULN Serum creatinine 2x ULN QT interval correct accord Fridericia 's formula ( QTcF ) ≤450 millisecond ( m ) male subject ≤470 ms female subject ECG Screening . Male subject surgically sterile willing use adequate contraceptive measure abstain heterosexual intercourse entire study treatment period . Female subject childbearing potential . Willingness ability understand nature study comply study follow procedure Acute promyelocytic leukemia ( FrenchAmericanBritish [ FAB ] M3 classification ) . Known AMLassociated ( 15 ; 17 ) , ( 8 ; 21 ) , ( 16 ; 16 ) , del ( 16q ) , inv ( 16 ) karyotype abnormality . Presence malignant disease within last 12 month , exception adequately treat insitu carcinoma , basal squamous cell carcinoma , nonmelanomatous skin cancer . Other malignancy consider casebycase basis . Lifethreatening illness AML , uncontrolled medical condition organ system dysfunction , Investigator 's opinion , could compromise subject 's safety , put study outcome risk . Uncontrolled symptomatic arrhythmia , unstable angina , Class 3 4 cardiac disease define New York Heart Association ( NYHA ) Functional Classification . Clinical evidence central nervous system ( CNS ) involvement . Are candidate intensive chemotherapy ( induction chemotherapy , bone marrow , stem cell transplant ) within next 4 month . Received one prior cycle HMA , previous bone marrow transplant intensive chemotherapy regimens either AHD AML . Received prior radiation therapy extramedullary disease within 2 week study enrollment . Received prior histone deacetylase ( HDAC ) inhibitor deacetylase ( DAC ) inhibitor permit Istodax ( romidepsin/depsipetide ) valproic acid . Received hematopoietic growth factor : erythropoietin , granulocyte colony stimulate factor ( GCSF ) , granulocyte macrophage colony stimulate factor ( GMCSF ) , thrombopoietin receptor agonist within 7 day ( 14 day Aranesp ) prior study enrollment . Have treat chemotherapeutic agent within 2 week 5 halflives first dose study drug , whichever long . Are treated systemic corticosteroid . Inhaled topical steroid well intermittent dexamethasone nausea vomit permit . Known history human immunodeficiency virus ( HIV ) active infection hepatitis C virus ( HCV ) hepatitis B virus ( HBV ) . Uncontrolled active systemic infection . Gastrointestinal ( GI ) tract disease , cause inability take oral medication , malabsorption syndrome , requirement IV alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease ( e.g. , Crohn 's disease , ulcerative colitis ) . Any disease ( ) , psychiatric condition , metabolic dysfunction , finding physical examination clinical laboratory test result would cause reasonable suspicion disease condition , contraindicate use study drug , may increase risk associate study participation , may affect interpretation result , would make subject inappropriate study .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>AML</keyword>
	<keyword>open label</keyword>
	<keyword>nonrandomized</keyword>
	<keyword>single arm</keyword>
	<keyword>elderly patient</keyword>
	<keyword>HMA</keyword>
	<keyword>newly diagnose</keyword>
</DOC>